Biotechnology · global
Anthropic Brings Claude Into the Scientific Workbench as Its AI Drug Discovery Ambitions Meet Experimental Reality
The point of Claude Science is not only to let researchers use a chat interface to search literature and run analyses. Anthropic is pushing itself into deeper waters in drug discovery; as models begin to propose biological hypotheses, the real test will shift to data traceability, experimental validation, and clinical responsibility.
Generative AI’s role in biomedicine is moving from “helping with writing and organizing data” into the inside of laboratory workflows. Anthropic recently launched the beta version of Claude Science, packaging Claude as a workbench for scientific research. More notably, foreign media have reported that the company is also preparing to start an internal preclinical drug discovery program, allowing AI not only to assist researchers but also to take part in proposing candidate therapeutic directions.
According to Anthropic’s public explanation, Claude Science is not an entirely new model, but a beta application for Claude Pro, Max, Team, and Enterprise users. It integrates common scientific tools, database queries, code execution, and visualization functions into the same environment, supports local macOS and Linux workflows, and can also connect to remote or high-performance computing environments. Its default use cases cover fields including genomics, single-cell analysis, proteomics, structural biology, and cheminformatics.
Specifically, tools of this kind can help researchers process single-cell RNA sequencing data, design CRISPR screens, predict protein structures, search scientific databases, or inspect compounds and molecular models. Anthropic says Claude Science can query more than 60 scientific databases and, through the NVIDIA BioNeMo Agent Toolkit, connect to life sciences models and libraries including Evo 2, Boltz-2, and OpenFold3. The product page also emphasizes that the system can preserve code, environments, and conversation records, making analyses easier to trace from data organization to manuscript drafts.
What truly takes this release beyond a standard AI tool update is that Anthropic’s head of life sciences, Eric Kauderer-Abrams, reportedly said in a briefing that the company will use Claude Science for internal preclinical drug discovery, with a focus on neglected diseases. If this statement is implemented, it would mean Anthropic is no longer just supplying research tools, but is attempting to enter candidate-drug hypothesis generation and early R&D decision-making. However, currently public information has not yet explained which diseases it will target, nor has it set out how laboratory work, animal studies, clinical trials, manufacturing, or commercial partnerships will be arranged.
This is also where the AI drug discovery narrative is most easily overestimated. Models can accelerate literature integration, propose molecular designs or screening directions, and even improve researchers’ efficiency in interpreting massive datasets. But a molecule or target that appears plausible must still pass through reproducible wet-lab experiments, toxicity evaluation, pharmacokinetics, human trials, and regulatory review. External experts’ attitude toward this kind of progress is usually not to reject AI, but to caution that AI can shorten some exploratory stages, yet cannot replace the evidentiary chain itself.
The early examples listed by Anthropic include target nomination at Manifold Bio, review workflows at the Allen Institute, and work related to glioma research with UCSF. These applications show that Claude Science is more like a research operations layer that connects data, code, and scientific models than a single system that “automatically invents new drugs.” For biomedical researchers, its value may lie in reducing cumbersome conversion and search costs. For patients and regulators, the key remains whether these workflows can produce transparent, auditable results that can be independently verified.
Background Context
Recently, AI drug discovery companies and major model providers have all been moving the story from “model capability” toward “R&D pipelines.” This is gradually changing the focus of competition: not who can show the smoothest molecular generation interface, but who can take hypotheses output by algorithms into experiments, clinical development, and regulatory standards. The significance of Claude Science is emerging at this turning point. If it is merely a more convenient scientific research assistant, the risk is relatively limited. If it becomes the underlying workbench for Anthropic’s own drug program, every step of data sourcing, model judgment, and experimental validation will be examined more strictly.